FUTURE OF HEALTHCARE

BD Forms Sustainable Medical Technology Institute to Reduce the Environmental Impact of its Product Portfolio

BD (Becton, Dickinson and Company) | April 23, 2022

BD Forms

BD a leading global medical technology company, announced the formation of the Sustainable Medical Technology Institute, a model of practice within the organization that will bring together BD researchers and engineers, as well as quality, regulatory, policy and operational expertise, to focus on reducing the environmental impact of the company's product portfolio in three areas, including adopting sustainable product design strategies, developing and deploying sustainable sterilization technologies, and addressing materials of concern.

The Institute will serve as an example of how the company continues to advance the world of health by prioritizing high-quality, safe products for patients, while furthering its environmental, social and governance strategy.

"As part of our ESG strategy, we made commitments in specific areas where we see the most opportunity for BD to create meaningful, measurable change over the next decade. In order to achieve these commitments, we established a set of goals to track and measure our success, and this includes how to reduce the environmental impact of our product portfolio and address our customers' sustainability needs. These priorities led us to form the Sustainable Medical Technology Institute."

Maureen Mazurek, vice president, sustainability and environmental health and safety at BD

Dr. Amit Limaye, director of the Sustainable Medical Technology Institute and director of sustainability research and development at BD, added, "By empowering our teams to tap into deep expertise in areas like engineering and materials science, coupled with access to breakthrough research, technologies, and government and academic partnerships, we are well-positioned to be the best environmental stewards of our portfolio. It is our vision to create a strategic roadmap that will be integral across the organization, demonstrating how an ethical and sustainable company can drive growth, while meeting patient and customer needs in the most environmentally sustainable way possible."

The Institute will operate in North America, Europe and Asia, and will collaborate with cross-functional teams within the company's business units, inclusive of research and development, regulatory, quality, policy and operations roles, with the goal of ensuring accountability and a streamlined approach to sustainability efforts, as well as further address sustainability needs within the industry and global regulatory bodies. Key initial efforts include reestablishing a set of minimum environmental and human health criteria for new products and product changes aligned with the company's 2030+ ESG commitments and goals, and identifying new ways to reduce, reuse, recycle or replace materials. These efforts will inform the company's product life cycle roadmap and enable adoption of a sustainable-by-design product development process.

About BDBD

is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. 

Spotlight

Alliance Healthcare is a leading international provider of pharmaceutical wholesaling, logistics, support with clinical trials and other innovative healthcare services and solutions to independent pharmacists and pharmaceutical manufacturers across Europe and beyond.

Spotlight

Alliance Healthcare is a leading international provider of pharmaceutical wholesaling, logistics, support with clinical trials and other innovative healthcare services and solutions to independent pharmacists and pharmaceutical manufacturers across Europe and beyond.

Related News

HEALTH TECHNOLOGY

Innovaccer and UpStream Healthcare Expand Partnership to Enhance Senior Care

UpStream | January 27, 2023

On January 26, 2023, Innovaccer, Inc., a data platform for healthcare, announced that it had entered a multiyear partnership with UpStream Healthcare, a value-based primary healthcare provider solution. This partnership entails UpStream more than doubling its population on Innovaccer's cloud-native platform in the coming year, scaling its exceptional value-based care model across the U.S. In April 2022, Innovaccer announced that UpStream Healthcare had selected the Innovaccer Health Cloud, Application Suite and Data Activation Platform to speed up its mission to transform senior healthcare with a full-risk model that improves outcomes, health equity, and care costs. Medicare and Medicare Advantage members on the UpStream platform have a 20-30% lower total cost of care and a 4.5-star quality rating. The company's platform physically embeds a pharmacist-led care team in every primary care physician's office and nurses who visit Medicare-eligible seniors at home. Adding to the point-of-care clinicians, other team members will close any clinical and quality gaps to care for all seniors in full-risk financial agreements. UpStream's clinical partners range from small independent primary care practices to IPAs, with two health systems and two ACO REACH entities supported. The company's data, analytics, and population health technology must scale quickly and cost-effectively to meet growing national demand. The company's platform, powered by Innovaccer Health Cloud, seamlessly integrates with EHRs of new providers and other healthcare IT. As a result, providers can easily access integrated workflows, unified patient records, and point-of-care analytics to deliver high-quality, low-cost care. The expanded partnership follows UpStream's $140 million Series B round, raised to scale its value-based care model across the nation. Since 2018, UpStream has grown to serve over 180,000 Medicare patients and 1,000 primary care physicians in three states. About Innovaccer A California-based health cloud company, Innovaccer Inc., accelerates healthcare innovation. The Innovaccer Health Cloud unifies patient data across systems and care settings, enabling healthcare organizations to develop modern, scalable applications that improve clinical, operational, and financial outcomes. Over 1,600 U.S. care settings use Innovaccer solutions, empowering more than 96,000 providers to transform care delivery and collaborate with life sciences companies and payers. KLAS and Black Book rank Innovaccer #1 in Data and Analytics and Population Health Technology, respectively. About UpStream Headquartered in Greensboro, North Carolina, UpStream is a primary healthcare solution provider that delivers value-based care to older patients and people with chronic conditions. The company offers an all-inclusive, risk-free solution for physicians that provides, finances, and sustains better outcomes by collaborating with healthcare practices and clinics. GAP-QTM (Guaranteed Advanced Payments for Quality) is UpStream's risk-free solution for physicians. GAP-QTM benefits physicians and practices by increasing income, professional satisfaction, and patients by lowering hospitalizations, decreasing copayments, and providing better benefits.

Read More

FUTURE OF HEALTHCARE

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Anumana | December 16, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe and Japan. Cardiac amyloidosis is a serious, progressive, and underdiagnosed rare disease that leads to heart failure.1 In patients with cardiac amyloidosis, the heart walls become stiff, making it difficult for the left ventricle to properly relax and fill with blood, while at the same time hampering its ability to squeeze and pump blood out of the heart. Symptoms and comorbidities associated with cardiac amyloidosis, such as shortness of breath, knee pain, bilateral carpal tunnel syndrome, kidney disease, and gastrointestinal issues, can vary and seem unrelated, making diagnosis difficult.2,3 “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress. We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” David McMullin, chief business officer of Anumana The research agreement with Pfizer will help deepen Anumana’s efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret. The ubiquitous nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier. “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.” Anumana was founded in 2021 in collaboration with the Mayo Clinic Platform. Anumana has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the U.S. FDA. These algorithms have been validated by over 75 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021, and another first of its kind batch enrolled prospective clinical impact study that demonstrated the effectiveness of AI-ECG to screen for undetected atrial fibrillation in normal sinus rhythm that was published in The Lancet in 2022. About Anumana Anumana, an AI-driven health technology company and portfolio company of nference, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More

HEALTH TECHNOLOGY

ZS and Abacus Insights Partner to Bring Innovative Data and Analytics to Health Plans

ZS and Abacus Insights | November 30, 2022

As ZS continues to help health plans evolve and transform, the firm announced an investment in and partnership with Abacus Insights, a healthcare technology leader with a groundbreaking offering in data usability that rapidly accelerates the achievement of key health plan goals including efficiency, equity, health services and member outcomes. “At ZS, we believe the future of healthcare is connected, with providers, health plans, pharma companies and other stakeholders working together. Usable data from Abacus Insights is a key enabler and connecter, and we take seriously our role in helping health plans innovate and excel. Partnerships like this one between ZS and Abacus Insights will be increasingly important in a connected health ecosystem.” ZS CEO Pratap Khedkar Abacus Insights offers the capability to consolidate and clean billions of pieces of structured and unstructured data from payers, providers, labs, digital apps and many more sources, providing end users with complete, current and accurate data sets that drive both operational and analytical uses. Through this partnership, health plans working with ZS gain access to usable data and a full suite of analytics and digital tools, unlocking insights from sales to operations to health outcomes and accelerating a path to decisions and actions. “Abacus Insights is proud to have the support of ZS both as an investor and partner. ZS recognizes that data usability is a game-changer in creating and scaling big performance advances for health plans,” said Minal Patel, Abacus Insights CEO. “Our companies share a common purpose to improve healthcare. Our combined health plan-specific expertise will accelerate our ability to help clients achieve their key transformational goals of better serving their members and leading healthcare change.” Usable data from Abacus Insights is already powering better quality reporting, more accurate risk adjustment and improved value-based contracting, care and payments. ZS Managing Principal Adam Siskind, who leads the firm’s health plan and provider vertical, said the partnership aims to help unlock use cases that health plans can leverage to fully realize the benefits of their analytics transformations. “There is no shortage of health plan challenges to solve, and it seems there is never enough capacity to unravel them. Our partnership with Abacus Insights will help our clients access the solutions they need to not only reach their goals but to do so efficiently and with scale,” Siskind said. “At ZS, we are proud to be the leading firm at the intersection of healthcare and analytics, so it only made sense to join forces with Abacus Insights, a company already recognized as the leader in health plan data usability in the U.S. Our combined capabilities allow us to achieve a new level of impact that all of our health plan clients seek—and all of their members deserve.” About ZS ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. About Abacus Insights Abacus Insights is a healthcare technology leader with the only data transformation platform and solutions built specifically for health plans. Focused on data usability, Abacus Insights gives payers a new level of control and flexibility with their data by developing accurate, timely, and robust ecosystems that can support analytics and operational use cases. Managing data for 21 million members, Abacus Insights partners with payers to deliver scalable solutions that drive strategic initiatives, control costs, and improve member lives and experiences.

Read More